180 related articles for article (PubMed ID: 23639540)
1. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.
Engers DW; Frist AY; Lindsley CW; Hong CC; Hopkins CR
Bioorg Med Chem Lett; 2013 Jun; 23(11):3248-52. PubMed ID: 23639540
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.
Williams E; Bullock AN
Bone; 2018 Apr; 109():251-258. PubMed ID: 28918311
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
[TBL] [Abstract][Full Text] [Related]
4. Development of an ALK2-biased BMP type I receptor kinase inhibitor.
Mohedas AH; Xing X; Armstrong KA; Bullock AN; Cuny GD; Yu PB
ACS Chem Biol; 2013; 8(6):1291-302. PubMed ID: 23547776
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors.
Cuny GD; Yu PB; Laha JK; Xing X; Liu JF; Lai CS; Deng DY; Sachidanandan C; Bloch KD; Peterson RT
Bioorg Med Chem Lett; 2008 Aug; 18(15):4388-92. PubMed ID: 18621530
[TBL] [Abstract][Full Text] [Related]
6. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
[TBL] [Abstract][Full Text] [Related]
7. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.
Hao J; Ho JN; Lewis JA; Karim KA; Daniels RN; Gentry PR; Hopkins CR; Lindsley CW; Hong CC
ACS Chem Biol; 2010 Feb; 5(2):245-53. PubMed ID: 20020776
[TBL] [Abstract][Full Text] [Related]
8. Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.
Yamamoto H; Sakai N; Ohte S; Sato T; Sekimata K; Matsumoto T; Nakamura K; Watanabe H; Mishima-Tsumagari C; Tanaka A; Hashizume Y; Honma T; Katagiri T; Miyazono K; Tomoda H; Shirouzu M; Koyama H
Bioorg Med Chem Lett; 2021 Apr; 38():127858. PubMed ID: 33609658
[TBL] [Abstract][Full Text] [Related]
9. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.
Chaikuad A; Alfano I; Kerr G; Sanvitale CE; Boergermann JH; Triffitt JT; von Delft F; Knapp S; Knaus P; Bullock AN
J Biol Chem; 2012 Oct; 287(44):36990-8. PubMed ID: 22977237
[TBL] [Abstract][Full Text] [Related]
10. Addressing species specific metabolism and solubility issues in a quinoline series of oral PDE4 inhibitors.
Lunniss C; Eldred C; Aston N; Craven A; Gohil K; Judkins B; Keeling S; Ranshaw L; Robinson E; Shipley T; Trivedi N
Bioorg Med Chem Lett; 2010 Jan; 20(1):137-40. PubMed ID: 19932963
[TBL] [Abstract][Full Text] [Related]
11. Bone morphogenetic protein 2 regulates cell-cell communication by down-regulating connexin43 expression in luteinized human granulosa cells.
Wu YT; Chang HM; Huang HF; Sheng JZ; Leung PC
Mol Hum Reprod; 2017 Mar; 23(3):155-165. PubMed ID: 27986931
[TBL] [Abstract][Full Text] [Related]
12. Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.
Engers DW; Bollinger SR; Felts AS; Vadukoot AK; Williams CH; Blobaum AL; Lindsley CW; Hong CC; Hopkins CR
Bioorg Med Chem Lett; 2020 Sep; 30(18):127418. PubMed ID: 32750526
[TBL] [Abstract][Full Text] [Related]
13. Novel Pyrazolo[1,5-a]pyrimidines as Translocator Protein 18 kDa (TSPO) Ligands: Synthesis, in Vitro Biological Evaluation, [(18)F]-Labeling, and in Vivo Neuroinflammation PET Images.
Damont A; Médran-Navarrete V; Cacheux F; Kuhnast B; Pottier G; Bernards N; Marguet F; Puech F; Boisgard R; Dollé F
J Med Chem; 2015 Sep; 58(18):7449-64. PubMed ID: 26280386
[TBL] [Abstract][Full Text] [Related]
14. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 7-(aminoalkyl)pyrazolo[1,5-a]pyrimidine derivatives as cathepsin K inhibitors.
Petek N; Štefane B; Novinec M; Svete J
Bioorg Chem; 2019 Mar; 84():226-238. PubMed ID: 30502634
[TBL] [Abstract][Full Text] [Related]
16. Selective synthesis of 1-substituted 4-chloropyrazolo[3,4-d]pyrimidines.
Babu S; Morrill C; Almstead NG; Moon YC
Org Lett; 2013 Apr; 15(8):1882-5. PubMed ID: 23574146
[TBL] [Abstract][Full Text] [Related]
17. Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors.
Fang Z; Wang TQ; Li H; Zhang G; Wu XA; Yang L; Peng YL; Zou J; Li LL; Xiang R; Yang SY
Bioorg Med Chem Lett; 2017 Jul; 27(14):3201-3204. PubMed ID: 28539219
[TBL] [Abstract][Full Text] [Related]
18. Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.
Scott JS; Brocklehurst KJ; Brown HS; Clarke DS; Coe H; Groombridge SD; Laber D; MacFaul PA; McKerrecher D; Schofield P
Bioorg Med Chem Lett; 2013 Jun; 23(11):3175-9. PubMed ID: 23628336
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
